CN102827050A - 亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其应用 - Google Patents
亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其应用 Download PDFInfo
- Publication number
- CN102827050A CN102827050A CN2012103454609A CN201210345460A CN102827050A CN 102827050 A CN102827050 A CN 102827050A CN 2012103454609 A CN2012103454609 A CN 2012103454609A CN 201210345460 A CN201210345460 A CN 201210345460A CN 102827050 A CN102827050 A CN 102827050A
- Authority
- CN
- China
- Prior art keywords
- och
- dmso
- thiosemicarbazone
- carboxylic acid
- nmr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- QIIPQYDSKRYMFG-UHFFFAOYSA-N phenyl hydrogen carbonate Chemical class OC(=O)OC1=CC=CC=C1 QIIPQYDSKRYMFG-UHFFFAOYSA-N 0.000 title abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 7
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 229910052799 carbon Inorganic materials 0.000 claims abstract description 6
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims abstract description 6
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 3
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 3
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 claims description 24
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 claims description 24
- -1 benzene oxygen carboxylic acid derivative Chemical class 0.000 claims description 20
- 150000001875 compounds Chemical class 0.000 claims description 17
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 15
- 101710147108 Tyrosinase inhibitor Proteins 0.000 claims description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000006243 chemical reaction Methods 0.000 claims description 8
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- BRWIZMBXBAOCCF-UHFFFAOYSA-N hydrazinecarbothioamide Chemical compound NNC(N)=S BRWIZMBXBAOCCF-UHFFFAOYSA-N 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 2
- 230000003000 nontoxic effect Effects 0.000 claims description 2
- 102000003425 Tyrosinase Human genes 0.000 abstract description 11
- 108060008724 Tyrosinase Proteins 0.000 abstract description 11
- 239000003112 inhibitor Substances 0.000 abstract description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 101
- 238000005160 1H NMR spectroscopy Methods 0.000 description 36
- 238000005481 NMR spectroscopy Methods 0.000 description 29
- 102000004316 Oxidoreductases Human genes 0.000 description 12
- 108090000854 Oxidoreductases Proteins 0.000 description 12
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 12
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 12
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Natural products OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 6
- 229960000271 arbutin Drugs 0.000 description 6
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 4
- 208000027089 Parkinsonian disease Diseases 0.000 description 4
- 206010034010 Parkinsonism Diseases 0.000 description 4
- 208000012641 Pigmentation disease Diseases 0.000 description 4
- 229940125904 compound 1 Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 201000001441 melanoma Diseases 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 3
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 3
- UNILWMWFPHPYOR-KXEYIPSPSA-M 1-[6-[2-[3-[3-[3-[2-[2-[3-[[2-[2-[[(2r)-1-[[2-[[(2r)-1-[3-[2-[2-[3-[[2-(2-amino-2-oxoethoxy)acetyl]amino]propoxy]ethoxy]ethoxy]propylamino]-3-hydroxy-1-oxopropan-2-yl]amino]-2-oxoethyl]amino]-3-[(2r)-2,3-di(hexadecanoyloxy)propyl]sulfanyl-1-oxopropan-2-yl Chemical compound O=C1C(SCCC(=O)NCCCOCCOCCOCCCNC(=O)COCC(=O)N[C@@H](CSC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)C(=O)NCC(=O)N[C@H](CO)C(=O)NCCCOCCOCCOCCCNC(=O)COCC(N)=O)CC(=O)N1CCNC(=O)CCCCCN\1C2=CC=C(S([O-])(=O)=O)C=C2CC/1=C/C=C/C=C/C1=[N+](CC)C2=CC=C(S([O-])(=O)=O)C=C2C1 UNILWMWFPHPYOR-KXEYIPSPSA-M 0.000 description 3
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010040829 Skin discolouration Diseases 0.000 description 3
- LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 3
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 3
- 229940125758 compound 15 Drugs 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- RGHHSNMVTDWUBI-UHFFFAOYSA-N 4-hydroxybenzaldehyde Chemical compound OC1=CC=C(C=O)C=C1 RGHHSNMVTDWUBI-UHFFFAOYSA-N 0.000 description 2
- 208000003351 Melanosis Diseases 0.000 description 2
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 2
- YAVVGPBYBUYPSR-UHFFFAOYSA-N benzene;oxygen Chemical class [O].C1=CC=CC=C1 YAVVGPBYBUYPSR-UHFFFAOYSA-N 0.000 description 2
- 229940126086 compound 21 Drugs 0.000 description 2
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 2
- 239000005452 food preservative Substances 0.000 description 2
- 235000019249 food preservative Nutrition 0.000 description 2
- 235000012055 fruits and vegetables Nutrition 0.000 description 2
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 2
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 2
- 229960004705 kojic acid Drugs 0.000 description 2
- HVGQWHMSVYODLJ-GFCCVEGCSA-N melanochrome Natural products CC1(C)Oc2cc3OC(=CC(=O)c3c(O)c2C[C@H]1O)CO HVGQWHMSVYODLJ-GFCCVEGCSA-N 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 239000000575 pesticide Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000013558 reference substance Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- UAOUIVVJBYDFKD-XKCDOFEDSA-N (1R,9R,10S,11R,12R,15S,18S,21R)-10,11,21-trihydroxy-8,8-dimethyl-14-methylidene-4-(prop-2-enylamino)-20-oxa-5-thia-3-azahexacyclo[9.7.2.112,15.01,9.02,6.012,18]henicosa-2(6),3-dien-13-one Chemical compound C([C@@H]1[C@@H](O)[C@@]23C(C1=C)=O)C[C@H]2[C@]12C(N=C(NCC=C)S4)=C4CC(C)(C)[C@H]1[C@H](O)[C@]3(O)OC2 UAOUIVVJBYDFKD-XKCDOFEDSA-N 0.000 description 1
- AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
- ABJSOROVZZKJGI-OCYUSGCXSA-N (1r,2r,4r)-2-(4-bromophenyl)-n-[(4-chlorophenyl)-(2-fluoropyridin-4-yl)methyl]-4-morpholin-4-ylcyclohexane-1-carboxamide Chemical compound C1=NC(F)=CC(C(NC(=O)[C@H]2[C@@H](C[C@@H](CC2)N2CCOCC2)C=2C=CC(Br)=CC=2)C=2C=CC(Cl)=CC=2)=C1 ABJSOROVZZKJGI-OCYUSGCXSA-N 0.000 description 1
- SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
- GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 1
- ITOFPJRDSCGOSA-KZLRUDJFSA-N (2s)-2-[[(4r)-4-[(3r,5r,8r,9s,10s,13r,14s,17r)-3-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]pentanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H](CC[C@]13C)[C@@H]2[C@@H]3CC[C@@H]1[C@H](C)CCC(=O)N[C@H](C(O)=O)CC1=CNC2=CC=CC=C12 ITOFPJRDSCGOSA-KZLRUDJFSA-N 0.000 description 1
- WWTBZEKOSBFBEM-SPWPXUSOSA-N (2s)-2-[[2-benzyl-3-[hydroxy-[(1r)-2-phenyl-1-(phenylmethoxycarbonylamino)ethyl]phosphoryl]propanoyl]amino]-3-(1h-indol-3-yl)propanoic acid Chemical compound N([C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)O)C(=O)C(CP(O)(=O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1C=CC=CC=1)CC1=CC=CC=C1 WWTBZEKOSBFBEM-SPWPXUSOSA-N 0.000 description 1
- IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- WZZBNLYBHUDSHF-DHLKQENFSA-N 1-[(3s,4s)-4-[8-(2-chloro-4-pyrimidin-2-yloxyphenyl)-7-fluoro-2-methylimidazo[4,5-c]quinolin-1-yl]-3-fluoropiperidin-1-yl]-2-hydroxyethanone Chemical compound CC1=NC2=CN=C3C=C(F)C(C=4C(=CC(OC=5N=CC=CN=5)=CC=4)Cl)=CC3=C2N1[C@H]1CCN(C(=O)CO)C[C@@H]1F WZZBNLYBHUDSHF-DHLKQENFSA-N 0.000 description 1
- ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
- TVTJUIAKQFIXCE-HUKYDQBMSA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynyl-1H-purine-6,8-dione Chemical compound NC=1NC(C=2N(C(N(C=2N=1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C)=O TVTJUIAKQFIXCE-HUKYDQBMSA-N 0.000 description 1
- NPRYCHLHHVWLQZ-TURQNECASA-N 2-amino-9-[(2R,3S,4S,5R)-4-fluoro-3-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-7-prop-2-ynylpurin-8-one Chemical compound NC1=NC=C2N(C(N(C2=N1)[C@@H]1O[C@@H]([C@H]([C@H]1O)F)CO)=O)CC#C NPRYCHLHHVWLQZ-TURQNECASA-N 0.000 description 1
- QBWKPGNFQQJGFY-QLFBSQMISA-N 3-[(1r)-1-[(2r,6s)-2,6-dimethylmorpholin-4-yl]ethyl]-n-[6-methyl-3-(1h-pyrazol-4-yl)imidazo[1,2-a]pyrazin-8-yl]-1,2-thiazol-5-amine Chemical compound N1([C@H](C)C2=NSC(NC=3C4=NC=C(N4C=C(C)N=3)C3=CNN=C3)=C2)C[C@H](C)O[C@H](C)C1 QBWKPGNFQQJGFY-QLFBSQMISA-N 0.000 description 1
- ZUNFPBNHELLPPP-UHFFFAOYSA-N 3-[4-(aminomethyl)-6-(trifluoromethyl)pyridin-2-yl]oxy-N-[2-(dimethylamino)ethyl]benzamide Chemical compound NCC1=CC(=NC(=C1)C(F)(F)F)OC=1C=C(C(=O)NCCN(C)C)C=CC=1 ZUNFPBNHELLPPP-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102000030523 Catechol oxidase Human genes 0.000 description 1
- 108010031396 Catechol oxidase Proteins 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 229940126657 Compound 17 Drugs 0.000 description 1
- 229940126639 Compound 33 Drugs 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- 101710157860 Oxydoreductase Proteins 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- PNUZDKCDAWUEGK-CYZMBNFOSA-N Sitafloxacin Chemical compound C([C@H]1N)N(C=2C(=C3C(C(C(C(O)=O)=CN3[C@H]3[C@H](C3)F)=O)=CC=2F)Cl)CC11CC1 PNUZDKCDAWUEGK-CYZMBNFOSA-N 0.000 description 1
- LJOOWESTVASNOG-UFJKPHDISA-N [(1s,3r,4ar,7s,8s,8as)-3-hydroxy-8-[2-[(4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-7-methyl-1,2,3,4,4a,7,8,8a-octahydronaphthalen-1-yl] (2s)-2-methylbutanoate Chemical compound C([C@H]1[C@@H](C)C=C[C@H]2C[C@@H](O)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)CC1C[C@@H](O)CC(=O)O1 LJOOWESTVASNOG-UFJKPHDISA-N 0.000 description 1
- SMNRFWMNPDABKZ-WVALLCKVSA-N [[(2R,3S,4R,5S)-5-(2,6-dioxo-3H-pyridin-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [[[(2R,3S,4S,5R,6R)-4-fluoro-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-hydroxyphosphoryl]oxy-hydroxyphosphoryl] hydrogen phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(=O)OP(O)(=O)OP(O)(=O)OP(O)(=O)OC[C@H]2O[C@H]([C@H](O)[C@@H]2O)C2C=CC(=O)NC2=O)[C@H](O)[C@@H](F)[C@@H]1O SMNRFWMNPDABKZ-WVALLCKVSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- XRWSZZJLZRKHHD-WVWIJVSJSA-N asunaprevir Chemical compound O=C([C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)OC(C)(C)C)C(C)(C)C)OC1=NC=C(C2=CC=C(Cl)C=C21)OC)N[C@]1(C(=O)NS(=O)(=O)C2CC2)C[C@H]1C=C XRWSZZJLZRKHHD-WVWIJVSJSA-N 0.000 description 1
- KGNDCEVUMONOKF-UGPLYTSKSA-N benzyl n-[(2r)-1-[(2s,4r)-2-[[(2s)-6-amino-1-(1,3-benzoxazol-2-yl)-1,1-dihydroxyhexan-2-yl]carbamoyl]-4-[(4-methylphenyl)methoxy]pyrrolidin-1-yl]-1-oxo-4-phenylbutan-2-yl]carbamate Chemical compound C1=CC(C)=CC=C1CO[C@H]1CN(C(=O)[C@@H](CCC=2C=CC=CC=2)NC(=O)OCC=2C=CC=CC=2)[C@H](C(=O)N[C@@H](CCCCN)C(O)(O)C=2OC3=CC=CC=C3N=2)C1 KGNDCEVUMONOKF-UGPLYTSKSA-N 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- OBNCKNCVKJNDBV-UHFFFAOYSA-N butanoic acid ethyl ester Natural products CCCC(=O)OCC OBNCKNCVKJNDBV-UHFFFAOYSA-N 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 229940125773 compound 10 Drugs 0.000 description 1
- 229940125797 compound 12 Drugs 0.000 description 1
- 229940126543 compound 14 Drugs 0.000 description 1
- 229940126142 compound 16 Drugs 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940125810 compound 20 Drugs 0.000 description 1
- 229940126208 compound 22 Drugs 0.000 description 1
- 229940125833 compound 23 Drugs 0.000 description 1
- 229940125961 compound 24 Drugs 0.000 description 1
- 229940125846 compound 25 Drugs 0.000 description 1
- 229940125851 compound 27 Drugs 0.000 description 1
- 229940127204 compound 29 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125898 compound 5 Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- XIMFCGSNSKXPBO-UHFFFAOYSA-N ethyl 2-bromobutanoate Chemical compound CCOC(=O)C(Br)CC XIMFCGSNSKXPBO-UHFFFAOYSA-N 0.000 description 1
- IXSZQYVWNJNRAL-UHFFFAOYSA-N etoxazole Chemical compound CCOC1=CC(C(C)(C)C)=CC=C1C1N=C(C=2C(=CC=CC=2F)F)OC1 IXSZQYVWNJNRAL-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 1
- 235000015320 potassium carbonate Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- FKRCODPIKNYEAC-UHFFFAOYSA-N propionic acid ethyl ester Natural products CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000012265 solid product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229940118172 sucrets Drugs 0.000 description 1
- 239000002512 suppressor factor Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 150000003700 vitamin C derivatives Chemical class 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
本发明公开了式I所示的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其作为酪氨酸酶抑制剂的应用。
其中，R1选自氢或一个羟基或多个羟基或1-6个碳的烷氧基；n=1-6时,R2选自氢;或n=0或n=3-6时，R2选自1-6个碳的直链烷基。
Description
技术领域
本发明涉及化妆品、食品、药物化学领域，具体涉及亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其作为酪氨酸酶抑制剂的应用。
技术背景
酪氨酸酶（EC 1.14.18.1，Tyrosinase）又称酚氧化酶、多酚氧化酶、儿茶酚氧化酶，
是结构复杂的多亚基的含铜氧化还原酶，广泛存在于微生物、动植物及人体中。酪氨酸酶具有独特的双重催化功能，是生物体内黑色素合成的关键酶，与人的衰老、人体的色素沉着性疾病有密切关联。因此，酪氨酸酶抑制剂可以用来治疗目前常见的黑色素沉着皮肤病如雀斑、黄褐斑、老年斑，目前，市场上使用的美白化妆品中添加的增白剂均是酪氨酸酶抑制剂，如熊果苷、维生素C衍生物以及一些天然产物提取物等。酪氨酸酶是果蔬中导致褐变的主要酶类，一些酪氨酸酶抑制剂已经应用于果蔬和其它食品的保鲜，如4-己基间苯二酚用于虾的保鲜。酪氨酸酶的高度表达导致大量的黑色素沉着，最近的研究表明，大量黑色素沉着与恶性黑色素瘤的发病有着密切关联，酪氨酸酶抑制剂有可能应用于恶性黑色素瘤的治疗。酪氨酸酶的活性水平过高和与帕金森综合症及其它神经退行性疾病的发展有关联，因此，酪氨酸酶抑制剂可能应用于治疗帕金森综合症和其它神经退行性疾病。昆虫表皮的酪氨酸酶可以催化产生黑色素，用于保护昆虫免受紫外线的辐射，酪氨酸酶也与昆虫蜕皮过程中的鞣化作用有 关，所以，酪氨酸酶是昆虫赖于生存的一种关键酶，因此，酪氨酸酶抑制剂将在新型生物杀虫剂方面有良好的应用前景。
目前市面常用的酪氨酸酶抑制剂的种类十分有限，主要包括熊果苷，曲酸、维生素C及其衍生物等，熊果苷安全性好，但其抑制活性低，价格高昂，维生素C价格低，安全性好，也存在活性太差而得不到大量使用，而曲酸活性较好，但由于有致癌作用而逐渐停止使用。鉴于酪氨酸酶抑制剂的广泛应用和良好的潜在应用前景，开发高效低毒的酪氨酸酶抑制剂已成为重要的研究方向。
酪氨酸酶抑制剂的活性测试方法见V.J.Hearing,Methods in Enzymology，vol.142,Academic Press,New York,1987,p 154.
发明内容：
本发明的目的是提供一类新的对酪氨酸酶具有高抑制活性的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其作为酪氨酸酶抑制剂的应用。
本发明还提供了包括上述亚甲基缩氨基硫脲基取代苯氧羧酸衍生物成分的药物组合物。
本发明是通过以下技术方案予以实现的：
式I所示的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物：
其中，R1选自氢或一个羟基或多个羟基或1-6个碳的烷氧基；
n=1-6时,R2选自氢;
或n=0或n=3-6时，R2选自1-6个碳的直链烷基。
本发明亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，包括其羧酸酯及其羧酸化合物，结构优选为式A、式B或式C：
本发明亚甲基缩氨基硫脲基取代苯氧羧酸衍生物的具体结构说明如表1-3所示：
表1.式A所示的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物具体结构
表2式B所示亚甲基缩氨基硫脲基取代苯氧羧酸衍生物具体结构
表3式C所示亚甲基缩氨基硫脲基取代苯氧羧酸衍生物具体结构
本发明化合物较优选为如下化合物：化合物7~9,化合物13、化合物15、化合物18～24和化合物26，它们的结构式如下：
式I所示亚甲基缩氨基硫脲基取代苯氧羧酸衍生物合成路线如下：
所述步骤a中
与Br(CH2)nCOOR2和K2CO3的物质的量的比为1:1.5:2，反应温度为回流条件，溶剂为干燥无水丙酮；所述步骤b中氨基硫脲与
的物质的量的比值为1:1，反应温度为回流条件，溶剂为干燥无水甲醇；所述步骤c中氢氧化钠的质量分数为15%，反应温度为室温，所述氢氧化钠与步骤b产物的物质的量比为60:1，盐酸的浓度为1N，调节溶液PH为2-3。
本发明的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，具有极好的酪氨酸酶抑制活性，可 以作为酪氨酸酶抑制剂，用于制备美白化妆品、食品保鲜剂、抗黑色素瘤药物、治疗帕金森综合症药物及生物杀虫剂。
本发明还提供一种药物组合物，包含至少一种所述的式I化合物作为活性成分，单独或结合一种或几种药学上可接受的、惰性的、无毒的赋形剂或载体。
所述组合物用于制备美白化妆品、食品保鲜剂、抗黑色素瘤药物、治疗帕金森综合症药物及生物杀虫剂。
具体实施方式：
以下是对本发明的进一步说明，而不是对本发明的限制。
实施例1、亚甲基缩氨基硫脲基-4-苯氧丁酸乙酯(化合物1)的制备
对羟基苯甲醛2.44g（20mmol）溶于40mL干燥丙酮，加入5.52g（40mmol）碳酸钾（微波活化）和溴丁酸乙酯5.85g（30mmol），加毕，于回流条件下搅拌8小时。TLC跟踪至反应完全。过滤，旋干溶剂，得到初产物。再用硅胶柱层析分离得中间体，收率74%。
将上述得到的中间体5mmol溶于20mL无水甲醇中，加入5mmol氨基硫脲，于回流条件下搅拌4小时，TLC跟踪至反应完全。待反应溶液冷却后，加入40mL乙酸乙酯，产生沉淀，过滤，得白色固体产物，即亚甲基缩氨基硫脲基-4-苯氧丙酸乙酯(化合物1)，收率86%。
同上述方法制备得到化合物2-9，22-24，29-31。
实施例2、亚甲基缩氨基硫脲基-4-苯氧丁酸（化合物11）的制备
取化合物1(2mmol)，加入15%（W/W）NaOH水溶液32克，常温搅拌4小时，于冰水浴条件下，往反应液中缓慢加入1N稀盐酸，调节溶液PH为2-3，产生固体沉淀，过滤，真空干燥，的白色固体，即为化合物11，产率94%。
同上述方法制备得到化合物10-21，25-28，32-35。
化合物1-35的结构鉴定由1H-NMR、13C NMR确认，图谱数据如下：
化合物1：
1H-NMR(300MHz,DMSO-d6):δ 11.37(s,1H,NH),8.16(s,1H,NH2),8.04(s,1H,NCH),7.95(s,1H,NH2),7.75(d,J=8.7Hz,2H,Ph-H),6.93(d,J=9.0Hz,2H,Ph-H),4.01-4.11(m,4H,OCH2CH2CH2,CH2CH3),2.46(t,J=7.2Hz,2H,OCH2CH2CH2),1.95-2.03(m,2H,OCH2CH2CH2),1.18(t,J=7.2Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ 177.5,172.4,159.8,142.2,128.8,126.6,114.5,66.5,59.8,30.0,24.1,14.0.
化合物2：
1H-NMR(300MHz,DMSO-d6):δ 11.32(s,1H,NH),8.11(s,1H,NH2),8.00(s,1H,NCH),7.90(s,1H,NH2),7.71(d,J=8.7Hz,2H,Ph-H),6.92(d,J=8.4Hz,2H,Ph-H),3.95-4.05(m,4H,OCH2CH2CH2CH2,CH2CH3),2.32(t,J=6.9Hz,2H,OCH2CH2CH2CH2),1.67(br s,4H,OCH2CH2CH2CH2),1.15(t,J=7.2Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ 177.5,172.6,160.0,142.2,128.8,126.5,114.5,67.1,59.6,48.5,33.0,27.9,21.1,14.0.
化合物3：
1H-NMR(300MHz,DMSO-d6):δ 11.34(s,1H,NH),8.12(s,1H,NH2),8.01(s,1H,NCH),7.89(s,1H,NH2),7.70(d,J=8.4Hz,2H,Ph-H),6.90(d,J=8.7Hz,2H,Ph-H),3.97-4.04(m,2H,CH2CH3),3.92(t,J=6.0Hz,2H,OCH2CH2CH2CH2CH2),2.24(t,J=6.9Hz,2H,OCH2CH2CH2CH2CH2),1.63-1.68(m,2H,OCH2CH2CH2CH2CH2),1.51-1.56(m,2H,OCH2CH2CH2CH2CH2),1.34-1.39(m,2H,OCH2CH2CH2CH2CH2),1.13(t,J=7.2Hz,3H,CH3). 13C NMR(75MHz,DMSO-d6):δ 177.5,172.7,160.0,142.2,128.8,126.5,114.4,67.3,59.5,33.3,28.2,24.9,24.1,14.0.
化合物4：
1H-NMR(300MHz,DMSO-d6):δ 11.34(s,1H,NH),8.17(s,1H,NH2),8.02(s,1H,NH2),7.99(s,1H,NCH),7.49(s,1H,Ph-H),7.11(d,J=8.4Hz,1H,Ph-H),6.88(d,J=8.4Hz,1H,Ph-H),3.94-4.02(m,4H,OCH2CH2CH2,CH2CH3),3.80(s,3H,OCH3),2.40(t,J=7.2Hz,2H,OCH2CH2CH2),1.89-1.98(m,2H,OCH2CH2CH2),1.12(t,J=7.2Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ 177.5,172.3,149.6,149.2,142.5,126.9,121.9,112.1,108.6,67.1,59.8,55.6,30.0,24.1,13.9.
化合物5：
1H-NMR(300MHz,DMSO-d6):δ 11.37(s,1H,NH),8.20(s,1H,NH2),8.06(s,1H,NH2),8.02(s,1H,NCH),7.54(s,1H,Ph-H),7.16(d,J=8.4Hz,1H,Ph-H),6.95(d,J=8.1Hz,1H,Ph-H),4.05-4.10(m,2H,CH2CH3),4.00(t,J=6.9Hz,2H,OCH2CH2CH2CH2),3.85(s,3H,OCH3),2.37(t,J=7.2Hz,2H,OCH2CH2CH2CH2),1.67-1.77(m,4H,OCH2CH2CH2CH2),1.19(t,J=7.2Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ 177.4,172.7,149.8,149.2,142.5,126.7,122.0,112.1,108.6,67.7,59.6,55.6,33.0,27.9,21.1,13.9.
化合物6：
1H-NMR(300MHz,DMSO-d6):δ 11.35(s,1H,NH),8.15(s,1H,NH2),8.00(s,1H,NH2),7.97(s,1H,NCH),7.50(s,1H,Ph-H),7.11(d,J=8.4Hz,1H,Ph-H),6.90(d,J=8.4Hz,1H,Ph-H),4.02-4.09(m,2H,CH2CH3),3.94(t,J=6.9Hz,2H,OCH2CH2CH2CH2CH2),3.80(s,3H,OCH3), 2.26(t,J=7.2Hz,2H,OCH2CH2CH2CH2CH2),1.64-1.72(m,2H,OCH2CH2CH2CH2CH2),1.52-1.59(m,2H,OCH2CH2CH2CH2CH2),1.34-1.41(m,2H,OCH2CH2CH2CH2CH2),1.14(t,J=6.9Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ 177.50,172.7,149.9,149.2,142.5,126.7,122.0,112.0,108.6,67.9,59.9,55.6,33.3,28.3,25.0,24.1,13.9.
化合物7：
1H-NMR(300MHz,DMSO-d6):δ 11.28(s,1H,Ph-OH),9.94(s,1H,NH),8.30(s,1H,NCH),8.04(s,1H,NH2),7.85(s,1H,NH2),7.81(d,J=7.2Hz,1H,Ph-H),6.45(d,J=7.5Hz,1H,Ph-H),6.42(s,1H,Ph-H),4.04-4.11(m,2H,CH2CH3),3.97(t,J=6.3Hz,2H,OCH2CH2CH2),2.45(t,J=7.2Hz,2H,OCH2CH2CH2),1.95-2.01(m,2H,OCH2CH2CH2),1.18(t,J=6.6Hz,3H,CH3).13CNMR(75MHz,DMSO-d6):δ 177.1,172.4,161.0,157.7,140.1,128.2,113.2,106.5,101.2,66.4,59.8,30.0,24.1,14.0.
化合物8：
1H-NMR(300MHz,DMSO-d6):δ 11.26(s,1H,Ph-OH),9.87(s,1H,NH),8.29(s,1H,NCH),8.01(s,1H,NH2),7.81(s,1H,NH2),7.73(d,J=9.0Hz,1H,Ph-H),6.41(d,J=7.5Hz,1H,Ph-H),6.38(s,1H,Ph-H),3.96-4.03(m,2H,CH2CH3),3.89(br s,2H,OCH2CH2CH2CH2),2.29(t,J=6.9Hz,2H,OCH2CH2CH2CH2),1.64(br s,4H,OCH2CH2CH2CH2),1.12(t,J=7.2Hz,3H,CH3).13CNMR(75MHz,DMSO-d6):δ 177.0,172.6,161.1,157.8,140.6,128.3,112.9,106.5,101.3,67.0,59.6,33.0,27.8,21.1,13.9.
化合物9：
1H-NMR(300MHz,DMSO-d6):δ 11.28(s,1H,Ph-OH),9.92(s,1H,NH),8.31(s,1H,NCH), 8.03(s,1H,NH2),7.84(s,1H,NH2),7.80(d,J=8.4Hz,1H,Ph-H),6.44(d,J=7.5Hz,1H,Ph-H),6.41(s,1H,Ph-H),4.02-4.09(m,2H,CH2CH3),3.93(t,J=6.3Hz,2H,OCH2CH2CH2CH2CH2),2.30(t,J=7.2Hz,2H,OCH2CH2CH2CH2CH2),1.66-1.73(m,2H,OCH2CH2CH2CH2CH2),1.53-1.61(m,2H,OCH2CH2CH2CH2CH2),1.37-1.45(m,2H,OCH2CH2CH2CH2CH2),1.18(t,J=7.2Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ 177.1,172.7,161.2,157.8,140.3,128.2,113.0,106.6,101.2,67.2,59.6,33.3,28.2,24.9,24.1,14.0.
化合物10：
1H-NMR(300MHz,DMSO-d6):δ 11.33(s,1H,NH),8.11(s,1H,NH2),7.99(s,1H,NCH),7.92(s,1H,NH2),7.73(d,J=8.7Hz,2H,Ph-H),6.93(d,J=8.7Hz,2H,Ph-H),4.72(s,2H,CH2).13CNMR(75MHz,DMSO-d6):δ 177.5,169.9,159.0,142.1,128.7,127.1,114.6,64.4.
化合物11：
1H-NMR(300MHz,DMSO-d6):δ 11.35(s,1H,NH),8.14(s,1H,NH2),8.03(s,1H,NCH),7.94(s,1H,NH2),7.74(d,J=8.7Hz,2H,Ph-H),6.97(d,J=8.7Hz,2H,Ph-H),4.03(t,J=6.6Hz,2H,OCH2CH2CH2),2.41(t,J=7.5Hz,2H,OCH2CH2CH2),1.92-2.01(m,2H,OCH2CH2CH2).13CNMR(75MHz,DMSO-d6):δ 177.5,174.0,159.9,142.3,128.8,126.6,114.5,66.6,30.0,24.1.
化合物12：
1H-NMR(300MHz,DMSO-d6):δ 11.35(s,1H,NH),8.14(s,1H,NH2),8.03(s,1H,NCH),7.94(s,1H,NH2),7.74(d,J=8.7Hz,2H,Ph-H),6.96(d,J=8.7Hz,2H,Ph-H),4.01(t,J=6.0Hz,2H,OCH2CH2CH2CH2),2.30(t,J=7.2Hz,2H,OCH2CH2CH2CH2),1.64-1.77(m,4H,OCH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.5,174.3,160.0,142.2,128.8,126.5, 114.5,67.2,33.2,28.0,21.1.
化合物13：
1H-NMR(300MHz,DMSO-d6):δ 11.32(s,1H,NH),8.11(s,1H,NH2),8.00(s,1H,NCH),7.90(s,1H,NH2),7.71(d,J=8.7Hz,2H,Ph-H),6.92(d,J=8.7Hz,2H,Ph-H),3.95(br s,2H,OCH2CH2CH2CH2CH2),2.25(t,J=6.6Hz,2H,OCH2CH2CH2CH2CH2),1.68(br s,2H,OCH2CH2CH2CH2CH2),1.55(brs,2H,OCH2CH2CH2CH2CH2),1.38(brs,2H,OCH2CH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.5,172.7,160.0,142.2,128.8,126.5,114.5,67.3,33.3,28.3,25.1,24.2.
化合物14：
1H-NMR(300MHz,DMSO-d6):δ 11.34(s,1H,NH),8.17(s,1H,NH2),8.04(s,1H,NH2),7.97(s,1H,NCH),7.54(s,1H,Ph-H),7.12(d,J=8.1Hz,1H,Ph-H),6.85(d,J=8.4Hz,1H,Ph-H),4.71(s,2H,CH2),3.84(s,3H,OCH3).13C NMR(75MHz,DMSO-d6):δ 117.4,169.9,149.1,148.8,142.3,127.4,121.7,112.3,108.9,64.8,55.7.
化合物15：
1H-NMR(300MHz,DMSO-d6):δ 11.33(s,1H,NH),8.17(s,1H,NH2),8.03(s,1H,NH2),7.97(s,1H,NCH),7.52(s,1H,Ph-H),7.12(d,J=7.8Hz,1H,Ph-H),6.96(d,J=7.8Hz,1H,Ph-H),3.98(t,J=7.2Hz,2H,OCH2CH2CH2),3.83(s,3H,OCH3),2.39(t,J=6.9Hz,2H,OCH2CH2CH2),1.95(br s,2H,OCH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.4,174.0,149.7,149.2,142.5,126.9,122.0,112.3,108.7,67.2,55.6,29.9,24.1.
化合物16：
1H-NMR(300MHz,DMSO-d6):δ 11.34(s,1H,NH),8.18(s,1H,NH2),8.04(s,1H,NH2),7.99(s,1H,NCH),7.53(s,1H,Ph-H),7.14(d,J=8.1Hz,1H,Ph-H),6.96(d,J=8.4Hz,1H,Ph-H),3.99(t,J=6.3Hz,2H,OCH2CH2CH2CH2),3.83(s,3H,OCH3),2.30(t,J=6.9Hz,2H,OCH2CH2CH2CH2),1.63-1.77(m,4H,OCH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ177.4,174.3,149.8,149.2,142.5,126.7,122.1,112.1,108.6,67.7,55.6,33.2,28.0,21.1.
化合物17：
1H-NMR(300MHz,DMSO-d6):δ 11.34(s,1H,NH),8.15(s,1H,NH2),8.04(s,1H,NH2),8.02(s,1H,NCH),7.52(s,1H,Ph-H),7.15(d,J=8.4Hz,1H,Ph-H),6.95(d,J=8.1Hz,1H,Ph-H),3.97(t,J=6.9Hz,2H,OCH2CH2CH2CH2CH2),3.83(s,3H,OCH3),2.25(t,J=7.2Hz,2H,OCH2CH2CH2CH2CH2),1.70-1.75(m,2H,OCH2CH2CH2CH2CH2),1.55-1.60(m,2H,OCH2CH2CH2CH2CH2),1.39-1.45(m,2H,OCH2CH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.3,174.4,149.9,149.1,142.6,126.7,122.1,112.1,108.6,68.0,55.6,33.6,28.3,25.1,24.2.
化合物18：
1H-NMR(300MHz,DMSO-d6):δ 11.28(s,1H,Ph-OH),10.06(s,1H,NH),8.28(s,1H,NCH),8.03(s,1H,NH2),7.84(s,1H,NH2),7.82(d,J=6.6Hz,1H,Ph-H),6.42(d,J=5.7Hz,1H,Ph-H),6.40(s,1H,Ph-H),4.66(s,2H,CH2).13C NMR(75MHz,DMSO-d6):δ 177.1,169.9,160.1,157.7,139.6,127.9,113.7,106.4,101.3,64.4.
化合物19：
1H-NMR(300 MHz,DMSO-d6):δ 11.25(s,1H,Ph-OH),10.10(s,1H,NH),8.27(s,1H,NCH), 7.98(s,1H,NH2),7.82(s,1H,NH2),7.78(d,J=8.7Hz,1H,Ph-H),6.45(s,1H,Ph-H),6.42(d,J=7.5Hz,1H,Ph-H),3.93(t,J=6.3Hz,2H,OCH2CH2CH2),2.36(t,J=7.2Hz,2H,OCH2CH2CH2),1.86-1.95(m,2H,OCH2CH2CH2),.13C NMR(75MHz,DMSO-d6):δ 177.0,174.1,161.0,157.8,140.1,128.0,113.1,106.5,101.2,66.5,30.0,24.0.
化合物20：
1H-NMR(300MHz,DMSO-d6):δ 11.28(s,1H,Ph-OH),10.00(s,1H,NH),8.31(s,1H,NCH),8.02(s,1H,NH2),7.85(s,1H,NH2),7.81(d,J=8.4Hz,1H,Ph-H),6.51(s,1H,Ph-H),6.44(d,J=7.5Hz,1H,Ph-H),3.96(t,J=5.4Hz,2H,OCH2CH2CH2CH2),2.30(t,J=7.2Hz,2H,OCH2CH2CH2CH2),1.65-1.72(m,4H,OCH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ177.0,174.3,161.2,157.8,140.3,128.1,113.0,106.6,101.2,67.1,33.2,27.9,21.1.
化合物21：
1H-NMR(300MHz,DMSO-d6):δ 11.20(s,1H,Ph-OH),10.17(s,1H,NH),8.26(s,1H,NCH),7.82(s,1H,NH2),7.75(s,1H,NH2),7.80(d,J=8.4Hz,1H,Ph-H),6.41(s,1H,Ph-H),6.38(d,J=8.4Hz,1H,Ph-H),3.84(t,J=6.0Hz,2H,OCH2CH2CH2CH2CH2),2.17(t,J=7.2Hz,2H,OCH2CH2CH2CH2CH2),1.58-1.63(m,2H,OCH2CH2CH2CH2CH2),1.45-1.50(m,2H,OCH2CH2CH2CH2CH2),1.28-1.35(m,2H,OCH2CH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 176.7,174.9,161.3,157.8,141.0,128.2,112.7,106.7,101.3,67.3,33.5,28.1,24.9,24.1.
化合物22：
1H-NMR(300 MHz,DMSO-d6):δ 11.49(s,1H,NH),8.29(s,1H,NH2),8.11(s,1H,NH2),8.07(s, 1H,NCH),7.47(s,1H,Ph-H),7.26-7.35(m,2H,Ph-H),6.96(d,J=6.3Hz,1H,Ph-H),4.03-4.12(m,4H,OCH2CH2CH2,CH2CH3),2.48(t,J=7.2Hz,2H,OCH2CH2CH2),1.97-2.03(m,2H,OCH2CH2CH2),1.19(t,J=7.2Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ 177.9,172.4,158.7,142.1,135.5,129.6,120.5,116.5,111.4,66.5,59.8,30.0,24.1,14.0.
化合物23：
1H-NMR(300MHz,DMSO-d6):δ 11.40(s,1H,NH),8.26(s,1H,NH2),8.10(s,1H,NH2),8.06(s,1H,NCH),7.45(s,1H,Ph-H),7.26-7.34(m,2H,Ph-H),6.96(d,J=7.5Hz,1H,Ph-H),4.00-4.09(m,4H,OCH2CH2CH2CH2,CH2CH3),2.37(t,J=6.9Hz,2H,OCH2CH2CH2CH2),1.67(br s,4H,OCH2CH2CH2CH2),1.18(t,J=7.2Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ 177.9,172.6,158.8,142.1,135.5,129.6,120.4,116.4,111.5,67.0,59.6,33.1,28.0,21.1,14.0.
化合物24：
1H-NMR(300MHz,DMSO-d6):δ 11.47(s,1H,NH),8.26(s,1H,NH2),8.10(s,1H,NH2),8.05(s,1H,NCH),7.45(s,1H,Ph-H),7.25-7.33(m,2H,Ph-H),6.95(d,J=7.8Hz,1H,Ph-H),3.98-4.09(m,4H,OCH2CH2CH2CH2CH2,CH2CH3),2.31(t,J=7.2Hz,2H,OCH2CH2CH2CH2CH2),1.70-1.74(m,2H,OCH2CH2CH2CH2CH2),1.55-1.62(m,2H,OCH2CH2CH2CH2CH2),1.40-1.48(m,2H,OCH2CH2CH2CH2CH2),1.18(t,J=6.9Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ177.9,172.7,158.9,142.1,135.5,129.6,120.4,116.4,111.5,67.3,59.6,33.4,28.3.25.0,24.2,14.0.化合物25：
1H-NMR(300MHz,DMSO-d6):δ 11.46(s,1H,NH),8.26(s,1H,NH2),8.10(s,1H,NH2),8.03(s,1H,NCH),7.47(s,1H,Ph-H),7.24-7.33(m,2H,Ph-H),6.96(d,J=6.0Hz,1H,Ph-H),4.77(s,2H, CH2).13C NMR(75MHz,DMSO-d6):δ 177.9,170.1,158.0,141.9,135.5,129.7,121.0,116.6,111.5,64.3.
化合物26：
1H-NMR(300MHz,DMSO-d6):δ 11.40(s,1H,NH),8.17(s,1H,NH2),8.06(s,1H,NH2),8.00(s,1H,NCH),7.43(s,1H,Ph-H),7.25-7.29(m,2H,Ph-H),6.93(d,J=6.0Hz,1H,Ph-H),4.00(br s,2H,OCH2CH2CH2),2.39(br s,2H,OCH2CH2CH2),1.93(br s,2H,OCH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.8,174.2,158.7,142.4,135.4,129.7,120.6,116.5,111.5,66.6,30.0,24.1.
化合物27：
1H-NMR(300MHz,DMSO-d6):δ 11.31(s,1H,NH),8.03(s,1H,NH2),7.98(br s,2H,NH2,NCH),7.33(s,1H,Ph-H),7.22-7.30(m,2H,Ph-H),6.91(d,J=7.5Hz,1H,Ph-H),3.94(t,J=6.0Hz,2H,OCH2CH2CH2CH2),2.25(t,J=7.2Hz,2H,OCH2CH2CH2CH2),1.61-1.67(m,4H,OCH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.6,174.8,158.7,142.9,135.1,129.8,120.3,116.5,111.7,67.1,33.0,27.9,21.1.
化合物28：
1H-NMR(300MHz,DMSO-d6):δ 11.31(s,1H,NH),8.03(s,1H,NH2),7.98(br s,2H,NH2,NCH),7.32(s,1H,Ph-H),7.21-7.29(m,2H,Ph-H),6.88(d,J=7.5Hz,1H,Ph-H),3.90(t,J=6.3Hz,2H,OCH2CH2CH2CH2CH2),2.18(t,J=6.9Hz,2H,OCH2CH2CH2CH2CH2),1.61-1.66(m,2H,OCH2CH2CH2CH2CH2),1.47-1.52(m,2H,OCH2CH2CH2CH2CH2),1.32-1.37(m,2H,OCH2CH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.6,174.9,158.8,142.9,135.1,129.8,120.2,116.4,111.8,67.3,33.5,28.2,25.0,24.1.
化合物29：
1H-NMR(300MHz,DMSO-d6):δ 11.47(s,1H,NH),8.50(s,1H,NCH),8.16(s,1H,NH2),8.06(d,J=7.8Hz,1H,Ph-H),7.92(s,1H,NH2),7.31(t,J=7.2Hz,1H,Ph-H),6.89-6.98(m,2H,Ph-H),3.97-4.06(m,4H,OCH2CH2CH2,CH2CH3),2.52(t,J=7.5Hz,2H,OCH2CH2CH2),1.92-2.00(m,2H,OCH2CH2CH2),1.14(t,J=7.2Hz,3H,CH3).13C NMR(75MHz,DMSO-d6):δ177.7,172.5,156.9,138.3,131.2,125.8,122.2,120.5,112.3,66.8,59.8,29.9,24.2,14.0.
化合物30：
1H-NMR(300MHz,DMSO-d6):δ 11.51(s,1H,NH),8.49(s,1H,NCH),8.15(s,1H,NH2),8.06(d,J=7.8Hz,1H,Ph-H),7.91(s,1H,NH2),7.31(t,J=7.2Hz,1H,Ph-H),6.89-6.97(m,2H,Ph-H),3.96-4.04(m,4H,OCH2CH2CH2CH2,CH2CH3),2.33(br s,2H,OCH2CH2CH2CH2),1.72(br s,4H,OCH2CH2CH2CH2),1.13(t,J=7.2Hz,3H,CH2).13C NMR(75MHz,DMSO-d6):δ177.7,172.6,157.1,138.3,131.1,125.8,122.2,120.4,112.3,67.4,59.6,33.1,28.0,21.0,14.0.
化合物31：
1H-NMR(300MHz,DMSO-d6):δ 11.47(s,1H,NH),8.47(s,1H,NCH),8.15(s,1H,NH2),8.07(d,J=7.8Hz,1H,Ph-H),7.92(s,1H,NH2),7.31(t,J=6.9Hz,1H,Ph-H),6.89-6.99(m,2H,Ph-H),3.94-4.06(m,4H,OCH2CH2CH2CH2CH2,CH2CH3),2.29(t,J=7.2Hz,2H,OCH2CH2CH2CH2CH2),1.68-1.73(m,2H,OCH2CH2CH2CH2CH2),1.54-1.62(m,2H,OCH2CH2CH2CH2CH2),1.42-1.49(m,2H,OCH2CH2CH2CH2CH2),1.14(t,J=7.2Hz,3H,CH3). 13C NMR(75MHz,DMSO-d6):δ 177.7,172.7,157.1,138.2,131.1,125.8,122.3,120.3,112.4,67.6,59.6,33.4,28.3,24.9,24.1,14.0.
化合物32：
1H-NMR(300MHz,DMSO-d6):δ 11.51(s,1H,NH),8.47(s,1H,NCH),8.15(s,1H,NH2),8.09(d,J=7.8Hz,1H,Ph-H),7.96(s,1H,NH2),7.30(t,J=6.9Hz,1H,Ph-H),6.92-6.99(m,2H,Ph-H),4.77(s,2H,CH2).13C NMR(75MHz,DMSO-d6):δ 177.8,170.0,156.2,138.0,131.0,126.3,122.5,121.0,112.4,64.8.
化合物33：
1H-NMR(300MHz,DMSO-d6):δ 11.35(s,1H,NH),8.40(s,1H,NCH),7.87-7.96(m,3H,Ph-H，NH2),7.31(t,J=6.6Hz,1H,Ph-H),6.92-6.97(m,2H,Ph-H),3.99(t,J=6.0Hz,2H,OCH2CH2CH2),2.42(t,J=7.2Hz,2H,OCH2CH2CH2),1.91-1.98(m,2H,OCH2CH2CH2).13CNMR(75MHz,DMSO-d6):δ 177.3,174.8,157.0,139.0,131.6,125.7,121.8,120.7,112.3,67.0,30.2,24.1.
化合物34：
1H-NMR(300MHz,DMSO-d6):δ 11.42(s,1H,NH),8.43(s,1H,NCH),7.97(s,1H,NH2),7.95(br s,1H,Ph-H),7.86(s,1H,NH2),7.31(t,J=7.2Hz,1H,Ph-H),6.89-6.97(m,2H,Ph-H),3.94(t,J=6.9Hz,2H,OCH2CH2CH2CH2),2.26(t,J=6.9Hz,2H,OCH2CH2CH2CH2),1.67(br s,4H,OCH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.4,174.8,157.1,138.9,131.5,125.7,121.9,120.5,112.4,67.5,33.2,27.9,21.0.
化合物35：
1H-NMR(300MHz,DMSO-d6):δ 11.46(s,1H,NH),8.44(s,1H,NCH),8.06(s,1H,NH2),8.01(d,J=6.9Hz,1H,Ph-H),7.89(s,1H,NH2),7.31(t,J=7.8Hz,1H,Ph-H),6.89-6.98(m,2H, Ph-H),3.94(t,J=6.0Hz,4H,OCH2CH2CH2CH2CH2),2.22(t,J=7.5Hz,2H,OCH2CH2CH2CH2CH2),1.64-1.71(m,2H,OCH2CH2CH2CH2CH2),1.49-1.56(m,2H,OCH2CH2CH2CH2CH2),1.39-1.47(m,2H,OCH2CH2CH2CH2CH2).13C NMR(75MHz,DMSO-d6):δ 177.5,174.7,157.2,138.5,131.4,125.8,122.0,120.4,112.4,67.6,33.5,28.3,24.9,24.1.
实施例3、亚甲基缩氨基硫脲基取代苯氧羧酸酯及其羧酸类化合物的体外酪氨酸酶抑制活性测试
测试方法见V.J.Hearing,Methods in Enzymology，vol.142,Academic Press,New York,1987,p 154.具体实施方法为：在1.5mL的离心管中分别加入10μL含不同浓度的抑制剂(用DMSO配制)，945μL磷酸缓冲溶液(pH=6.8)以及5μL的0.45mg/mL酪氨酸酶的磷酸缓冲溶液(pH=6.8)，在25℃恒温水浴中保温10分钟，然后加入40μL L-DOPA(1.50mg/mL)溶液迅速充分混匀启动反应，在25℃恒温条件下测定波长为475nm的光密度值，由其随时间的增长直线的斜率计算出酶的活性（消光系数ε=3600M-1cm-1）。并用对照扣除缓冲溶液对本试验的影响。
由此方法测得的亚甲基缩氨基硫脲基取代苯氧羧酸酯及其羧酸类化合物的体外酪氨酸酶抑制活性数据如表4所示。
表4.亚甲基缩氨基硫脲基取代苯氧羧酸衍生物的体外酪氨酸酶a抑制活性（IC50值）
a:酪氨酸酶（EC 1.14.18.1，Tyrosinase）,来源于蘑菇。
b:IC50，指半数抑制浓度。
通过表中所列数据，可以得出：所有化合物均表现出高度的酪氨酸酶抑制活性，与对照物熊果苷相比（本实验测试IC50值为为7300μM，文献值为5300μM-8400μM，见Funayama,M.;Arakawa,H.;Yamamoto,R.;Nishino,T.;Shin,T.;Murao,S.Biosci.Biotech.Biochem.1995,59,143.和Shi,Y.;Chen,Q.X.;Wang,Q.;Song,K.K.;Qiu,L.Food Chem.2005,92,707.），其抑制活性提高了2-5个数量级；3位羟基取代的亚甲基缩氨基硫脲基苯氧羧酸衍生物的酪氨酸酶抑制活性最高，化合物21的活性达到81nM，相当于对照品熊果苷的近十万倍。化合物7~9,化合物13、化合物15、化合物18～24和化合物26活性比化合物21低十倍，相当于对照品熊果苷的近万倍。
Claims (7)
1.式I所示的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物：
其中，R1选自氢或一个羟基或多个羟基或1-6个碳的烷氧基；
n=1-6时,R2选自氢;
或n=0或n=3-6时，R2选自1-6个碳的直链烷基。
2.亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其特征在于，选自如下化合物：
3.根据权利要求1或2所述的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其特征在于，选
自如下化合物：
4.权利要求1或2所述的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物作为酪氨酸酶抑制剂的应用。
5.权利要求1所述的亚甲基缩氨基硫脲基取代苯氧羧酸衍生物的制备方法，其特征在于合成路线如下：
所述步骤a中
与Br(CH2)nCOOR2和K2CO3的物质的量的比为1:1.5:2，反应温度为56~58℃，溶剂为干燥无水丙酮；所述步骤b中氨基硫脲与
的物质的量的比值为1:1，反应温度为65~70℃，溶剂为干燥无水甲醇；所述步骤c中氢氧化钠的质量分数为15%，反应温度为室温，所述氢氧化钠与步骤b产物的物质的量比为60:1，盐酸的浓度为1N，调节溶液PH为2-3。
6.药物组合物，包含至少一种权利要求1所述的式I化合物作为活性成分，单独或结合一种
或几种药学上可接受的、惰性的、无毒的赋形剂或载体。
7.权利要求6所述的药物组合物作为酪氨酸酶抑制剂的应用。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210345460.9A CN102827050B (zh) | 2012-09-17 | 2012-09-17 | 亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其应用 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210345460.9A CN102827050B (zh) | 2012-09-17 | 2012-09-17 | 亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102827050A true CN102827050A (zh) | 2012-12-19 |
| CN102827050B CN102827050B (zh) | 2014-10-22 |
Family
ID=47330393
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210345460.9A Expired - Fee Related CN102827050B (zh) | 2012-09-17 | 2012-09-17 | 亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其应用 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102827050B (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104326957A (zh) * | 2014-10-11 | 2015-02-04 | 中国广州分析测试中心 | 氨基苯乙酮缩氨基硫脲衍生物及其应用 |
| CN105439926A (zh) * | 2015-11-27 | 2016-03-30 | 中国广州分析测试中心 | 烷基取代苯甲醛或苯乙酮缩氨基硫脲衍生物及其作为酪氨酸酶抑制剂的应用 |
| CN108047105A (zh) * | 2017-12-01 | 2018-05-18 | 广东轻工职业技术学院 | 3-/4-酯基取代苯甲醛缩氨基硫脲衍生物及其制备与应用 |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE847893C (de) * | 1943-11-04 | 1952-08-28 | Bayer Ag | Verfahren zur Herstellung von Thiosemicarbazonen |
| DE870553C (de) * | 1944-01-25 | 1953-03-16 | Bayer Ag | Verfahren zur Herstellung von Thiosemicarbazonen |
| JPH059165A (ja) * | 1991-02-18 | 1993-01-19 | Mitsubishi Petrochem Co Ltd | 置換フエノキシカルボン酸アミド誘導体 |
| JP2001354511A (ja) * | 2000-06-12 | 2001-12-25 | Shiseido Co Ltd | 美白剤およびこれを配合した皮膚外用剤 |
| CN101040824A (zh) * | 2007-04-20 | 2007-09-26 | 厦门大学 | 对二甲氨基苯甲醛缩氨基硫脲在美白化妆品中的应用 |
| CN101755801A (zh) * | 2010-01-25 | 2010-06-30 | 中国农业大学 | 取代苯基呋喃甲醛缩氨基硫脲类化合物作为昆虫酪氨酸酶抑制剂的用途 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20070218132A1 (en) * | 2004-12-23 | 2007-09-20 | Actial Farmaceutica Lda. | Device and method for identifying and treating vaginal affections |
-
2012
- 2012-09-17 CN CN201210345460.9A patent/CN102827050B/zh not_active Expired - Fee Related
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE847893C (de) * | 1943-11-04 | 1952-08-28 | Bayer Ag | Verfahren zur Herstellung von Thiosemicarbazonen |
| DE870553C (de) * | 1944-01-25 | 1953-03-16 | Bayer Ag | Verfahren zur Herstellung von Thiosemicarbazonen |
| JPH059165A (ja) * | 1991-02-18 | 1993-01-19 | Mitsubishi Petrochem Co Ltd | 置換フエノキシカルボン酸アミド誘導体 |
| JP2001354511A (ja) * | 2000-06-12 | 2001-12-25 | Shiseido Co Ltd | 美白剤およびこれを配合した皮膚外用剤 |
| CN101040824A (zh) * | 2007-04-20 | 2007-09-26 | 厦门大学 | 对二甲氨基苯甲醛缩氨基硫脲在美白化妆品中的应用 |
| CN101755801A (zh) * | 2010-01-25 | 2010-06-30 | 中国农业大学 | 取代苯基呋喃甲醛缩氨基硫脲类化合物作为昆虫酪氨酸酶抑制剂的用途 |
Non-Patent Citations (3)
| Title |
|---|
| KRASSOWSKA等: "Reactions and transformations of phenoxyalkanecarboxylic acid formyl derivatives", 《PRZEMYSL CHEMICZNY》, vol. 52, no. 11, 31 December 1973 (1973-12-31), pages 741 * |
| LIANG-HUA CHEN等: "Synthesis and Antityrosinase Mechanism of Benzaldehyde Thiosemicarbazones: Novel Tyrosinase Inhibitors", 《J.AGRIC.FOOD.CHEM.》, vol. 60, 17 January 2012 (2012-01-17), pages 1542 - 1 * |
| RAMON GARCIA-DOMENECH: "application of molecular topology to the prediction of the phenoloxidase inhibition by a group of benzaldehyde thiosemicarbazone and their derivatives", 《AFINIDAD》, vol. 65, no. 538, 31 December 2008 (2008-12-31) * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104326957A (zh) * | 2014-10-11 | 2015-02-04 | 中国广州分析测试中心 | 氨基苯乙酮缩氨基硫脲衍生物及其应用 |
| CN104326957B (zh) * | 2014-10-11 | 2016-06-08 | 中国广州分析测试中心 | 氨基苯乙酮缩氨基硫脲衍生物及其应用 |
| CN105439926A (zh) * | 2015-11-27 | 2016-03-30 | 中国广州分析测试中心 | 烷基取代苯甲醛或苯乙酮缩氨基硫脲衍生物及其作为酪氨酸酶抑制剂的应用 |
| CN105439926B (zh) * | 2015-11-27 | 2017-12-01 | 中国广州分析测试中心 | 烷基取代苯甲醛或苯乙酮缩氨基硫脲衍生物及其作为酪氨酸酶抑制剂的应用 |
| CN108047105A (zh) * | 2017-12-01 | 2018-05-18 | 广东轻工职业技术学院 | 3-/4-酯基取代苯甲醛缩氨基硫脲衍生物及其制备与应用 |
| CN108047105B (zh) * | 2017-12-01 | 2020-06-26 | 广东轻工职业技术学院 | 3-/4-酯基取代苯甲醛缩氨基硫脲衍生物及其制备与应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102827050B (zh) | 2014-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | Dictyoquinazols A, B, and C, new neuroprotective compounds from the mushroom Dictyophora indusiata | |
| CN102827050B (zh) | 亚甲基缩氨基硫脲基取代苯氧羧酸衍生物，其制备方法及其应用 | |
| NO20083315L (no) | 3,5-substituert piperidin-bestanddeler som renin-inhibitorer | |
| JP5965915B2 (ja) | ２−ピロン | |
| EP3691669B1 (fr) | Extraits racinaires de plantes du genre morus et leurs utilisations | |
| US5863939A (en) | Creatine ascorbates and a method of producing them | |
| JP2010505441A (ja) | ケンペロール−３−ｏ−ルチノシドを製造する方法及びこれを含有する皮膚外用剤組成物 | |
| CN102827049A (zh) | （氨基硫脲缩甲醛基）苯氧乙酸衍生物及其应用 | |
| EP3127532B1 (en) | Methods for promoting wound healing and for preparing the compound used in the method | |
| CN103006449B (zh) | 酪氨酸酶抑制剂及其制备方法 | |
| JP2010535821A (ja) | チロシナーゼ阻害剤 | |
| CN108033881B (zh) | 一种半天然来源的酪氨酸酶抑制剂及其制备方法与应用 | |
| JP5049480B2 (ja) | 美白剤および抗酸化剤ならびに活性酸素除去剤 | |
| JP5731653B2 (ja) | ２，２’−フロイン誘導体および皮膚を明るくするためのその使用 | |
| CN105439926B (zh) | 烷基取代苯甲醛或苯乙酮缩氨基硫脲衍生物及其作为酪氨酸酶抑制剂的应用 | |
| CN104326957B (zh) | 氨基苯乙酮缩氨基硫脲衍生物及其应用 | |
| JP5212969B2 (ja) | クロマン化合物およびその製造方法 | |
| JP2007513100A (ja) | フラボノイド誘導体 | |
| TW201204740A (en) | Compounds and method for inhibiting the activity of gelatinase and collagenase | |
| JPH06199679A (ja) | チロシナ−ゼ活性阻害剤 | |
| CN105294527B (zh) | 芳基取代苯甲醛或苯乙酮缩氨基硫脲衍生物及其作为酪氨酸酶抑制剂的应用 | |
| WO2008129188A1 (fr) | Procédé de dépigmentation des matières kératiniques à l'aide de composés carbamates de vitamine c, et utilisations desdits composés | |
| CN105017194B (zh) | 含愈创兰烃薁结构的酪氨酸酶抑制剂及其制备方法与应用 | |
| CN108727321A (zh) | 没食子酸曲酸酯类化合物及其作为酪氨酸酶抑制剂的应用 | |
| CN110156733B (zh) | 一种酪氨酸酶抑制剂及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20141022 Termination date: 20180917 |